19.85
+1.3(+7.01%)
Currency In USD
| Previous Close | 18.55 |
| Open | 18.73 |
| Day High | 20.11 |
| Day Low | 18.73 |
| 52-Week High | 26.22 |
| 52-Week Low | 6.36 |
| Volume | 3.87M |
| Average Volume | 2.97M |
| Market Cap | 2.84B |
| PE | -5.48 |
| EPS | -3.62 |
| Moving Average 50 Days | 19.46 |
| Moving Average 200 Days | 13.4 |
| Change | 1.3 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $830.54 as of December 19, 2025 at a share price of $19.85. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $1,479.14 as of December 19, 2025 at a share price of $19.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 11, 2025 9:05 PM GMT
WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the clo
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
GlobeNewswire Inc.
Dec 10, 2025 2:42 AM GMT
WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pri
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
GlobeNewswire Inc.
Dec 08, 2025 11:30 AM GMT
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observe